← All trials
NCT06378697
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 10, 2023
- Primary completion
- Feb 28, 2025
- Completion date
- Apr 30, 2026
- First posted
- Apr 22, 2024
- Last posted
- Apr 22, 2024
- Enrollment
- 510
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Akeso Pharmaceuticals, Inc.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.